NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06027268 2026-02-03
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT06955156 2025-05-02
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05113966 2025-01-29
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04799249 2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3 Completed
NCT02978716 2022-03-23
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
Phase 2 Terminated